Proactive Investors - Run By Investors For Investors

ValiRx updates on second round of funding discussions

The company has provided some detail on a potential second financing round
graphic with the word funding
A follow-on convertible and warrant funding arrangement is in negotiation

ValiRx Plc (LON:VAL) updated on a potential second round of funding as it provided some minor and revised guidance on the first financing round.

Last month the drug developer said it had brokered a subscription agreement with European High Growth Opportunities SF for £1.278mln at 0.6p done in three equal £426,000 tranches. ValiRx said today that the shares related to the second payment instalment will be admitted for trading on May 23 rather than May 21.

A follow-on convertible and warrant funding arrangement with the same investor is in negotiation, though definitive documentation has yet to be inked and shareholder approval needs to be sought and given, it added.

However, the company pointed out that the first £500,000 tranche of the planned second funding round has what is called a ‘make whole amount’ that ensures the subscription price can be reduced if ValiRx’s share price falls. For more information on how this calculated, click here.

There is also a £150,000 break fee plus and an additional amount in the event the share price falls.

“The company advises that it is commencing discussions with the Investor to amend the basis that is used to calculate the quantum of the break fee,” ValiRx said.

“The company does not expect the outcome of these discussions on the quantum of the Break Fee to have an adverse impact on the company.”

View full VAL profile View Profile

ValiRx Plc Timeline

Big Picture
May 02 2019

Related Articles

lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use